Evidence map›Paper›PMID 38093743›Full record

ArticleJACC. Basic to translational science2023

Protective Effect of Ticagrelor Against Infective Endocarditis Induced by Virulent

Cécile Oury, Severien Meyers, Nicolas Jacques, Kirsten Leeten, Zheshen Jiang, Lucia Musumeci, Marleen Lox, Margaux Debuisson, Eric Goffin, Bernard Pirotte and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 3 countries.

Cécile OuryLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
Severien MeyersCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Nicolas JacquesLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
Kirsten LeetenLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
Zheshen JiangLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
Lucia MusumeciLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
Marleen LoxCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Margaux DebuissonLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
Eric GoffinLaboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Centre Hospitalier Universitaire, Sart Tilman, Liège, Belgium.
Bernard PirotteLaboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Centre Hospitalier Universitaire, Sart Tilman, Liège, Belgium.
Philippe DelvenneDepartment of Pathology, Centre Hospitalier Universitaire of Liège, Liège, Belgium.
Alain NchimiLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
Cédric HubertCIRM, Laboratory of Pharmaceutical Analytical Chemistry, University of Liège, Liège, Belgium.
Mélanie HeptiaCIRM, Laboratory of Pharmaceutical Analytical Chemistry, University of Liège, Liège, Belgium.
Philippe HubertCIRM, Laboratory of Pharmaceutical Analytical Chemistry, University of Liège, Liège, Belgium.
Marijke J E KuijpersDepartment of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.
Thomas VanasscheCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Kimberly MartinodCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Peter VerhammeCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Patrizio LancellottiLaboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
University of Liège · BEKU Leuven · BEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to its potent antiplatelet activity, ticagrelor possesses antibacterial properties against gram-positive bacteria. We wondered whether the typical clinical dosage of ticagrelor could prevent the development of infective endocarditis caused by highly virulent

Indexed as

bacterial virulenceinfective endocarditisStaphylococcus aureusticagrelor

Identifiers

PMID38093743
PMCPMC10714181
OpenAlexW4378070163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.